抗VEGF治疗糖尿病黄斑水肿时视力与中心子区厚度变化的相关因素:Protocol T随机临床试验探索性分析
该研究为Protocol T随机临床试验的事后分析,纳入660例中心受累型糖尿病黄斑水肿伴视力损害患者,评估抗VEGF治疗2年时基线因素与视力及OCT中心子区厚度变化的关系,并检验因素与药物间交互作用。结果显示较低HbA1c、较年轻、无既往全视网膜光凝者视力改善更佳,非洲裔美国人和中心子区视网膜下液者厚度下降更明显,各预测因素与具体抗VEGF药物间无交互作用。
要点
- HbA1c每升高1%,视力改善减少约1字母,强调血糖控制重要性。
- 无既往PRP且DR程度轻于重度非增殖期者视力改善约多3字母。
核心结论
- 较低HbA1c水平与抗VEGF治疗后视力改善幅度相关,支持糖尿病患者加强血糖控制。
- 较年轻患者和无既往PRP者可能获得比年长或有PRP史者更大的视力改善。
- 各预测因素与具体抗VEGF药物之间未发现交互作用。
研究设计与样本
- Protocol T多中心随机临床试验的事后分析,分析于2016年12月至2017年12月进行。
- 2012年8月22日至2013年8月28日入组660例中心受累型DME伴视力损害患者(约20/32-20/320)。
- 干预为玻璃体腔注射阿柏西普2.0mg(201眼)、贝伐珠单抗1.25mg(185眼)或雷珠单抗0.3mg(192眼)。
- 分析样本为578例参与者,中位年龄61岁(IQR 54-67)。
主要发现
- HbA1c每升高1%,视力改善减少1字母(95%CI -1.5至-0.5,P<.001),VA AUC分析减少0.5字母(95%CI -0.9至-0.2,P<.001)。
- 无既往PRP且DR轻于重度非增殖期者较有PRP史者视力改善约多3字母(95%CI 0.9-5.4,P=.007),VA AUC分析(95%CI 1.3-4.2,P<.001)。
- 非洲裔美国参与者中心子区厚度下降较白人参与者多27.3μm(P=.01)。
- 有中心子区视网膜下液者中心子区厚度下降较无此OCT特征者多22.9μm(P=.01)。
临床怎么用
- 对于DME患者启动抗VEGF治疗时,应关注HbA1c水平并鼓励血糖控制以优化视力获益。
- 年长患者或有既往PRP史者预期视力改善可能较小,需合理设定治疗期望。
- 选择抗VEGF药物时无需基于这些基线因素考虑药物交互作用。
局限性
- 本研究为事后探索性分析,结果需谨慎解读。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Identifying the factors that are associated with the magnitude of treatment benefits from anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) may help refine treatment expectations. OBJECTIVE: To identify the baseline factors that are associated with vision and anatomic outcomes when managing DME with anti-VEGF and determine if there are interactions between factors and the agent administered. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of data from the Diabetic Retinopathy Clinical Research Network multicenter randomized clinical trial , Protocol T, was conducted between December 2016 and December 2017. Between August 22, 2012, and August 28, 2013, 660 participants were enrolled with central-involved DME and vision impairment (approximate Snellen equivalent, 20/32-20/320). INTERVENTIONS: Repeated 0.05-mL intravitreous injections of 2.0-mg aflibercept (201 eyes), 1.25-mg bevacizumab (185 eyes), or 0.3-mg ranibizumab (192 eyes) per protocol. MAIN OUTCOMES AND MEASURES: Change in visual acuity (VA) and optical coherence tomography (OCT) central subfield thickness at 2 years and change in VA over 2 years (area under the curve [AUC]). RESULTS: Among 578 participants, the median age (interquartile range) was 61 (54-67) years. Across anti-VEGF treatment groups, each baseline factor was associated with mean improvement in VA and a reduction in central DME compared with the baseline. For every decade of participant age, the mean VA improvement was reduced by 2.1 letters (95% CI, -3.0 to -1.2; P < .001) in the VA and 1.9 letters (95% CI, -2.4 to -1.3; P < .001) in the VA AUC analyses. For each 1% increase in hemoglobin A1c levels, VA improvement was reduced by 1 letter in the VA (95% CI, -1.5 to -0.5; P < .001) and 0.5 letters (95% CI, -0.9 to -0.2; P < .001) in the VA AUC analyses. Eyes with no prior panretinal photocoagulation (PRP) and less than severe nonproliferative diabetic retinopathy had an approximately 3-letter improvement in the VA (95% CI, 0.9-5.4; P = .007) and VA AUC (95% CI, 1.3-4.2; P < .001) analyses compared with eyes with prior PRP. On average, African American participants had greater reductions in central subfield thickness compared with eyes of white participants (-27.3 μm, P = .01), as did eyes with central subretinal fluid compared with eyes without this OCT feature (-22.9 μm, P = .01). There were no interactions between the predictive factors and the specific anti-VEGF agent that was administered for any VA or OCT outcome. CONCLUSIONS AND RELEVANCE: Lower hemoglobin A1c levels were associated with the magnitude of vision improvement following anti-VEGF therapy, providing further evidence to encourage glycemic control among persons with diabetes. Younger patients and those without prior PRP might expect greater improvement in VA than older patients or those with prior PRP.
引用
- Bressler SB, Odia I, Maguire MG, et al. Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial. JAMA Ophthalmol. 2019. PMID: 30676635. doi:10.1001/jamaophthalmol.2018.6786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。